Blue Cross Blue Shield cited high costs and a surge in spending on GLP-1 drugs. "We’ve made this decision after careful consideration and to be responsive to customers who’ve expressed to us ...

Costs for five of the GLP-1 drugs — Ozempic, Mounjaro, Wegovy, Zepbound, and Saxenda — topped $300 million for Boston-based Blue Cross last year, more than double what it spent in 2023.